Table 2.
Safety outcomes in patients with FSGS
| n (%) | Dapagliflozin (N = 45) | Placebo (N = 58) |
|---|---|---|
| Adverse event leading to study drug discontinuation | 3 (6.7) | 3 (5.2) |
| Any serious adverse eventa | 9 (20.0) | 16 (27.6) |
a
Includes death.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.